Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/236380
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Antiretroviral Treatment for HIV Elite Controllers? |
Autor: | Ruiz-Mateos, Ezequiel CSIC ORCID; Poveda, Eva; Lederman, Michael M. | Palabras clave: | Elite Control HIV Immune activation Inflammation Cardiovascular diseases Transmission |
Fecha de publicación: | 19-may-2020 | Citación: | Pathogens and Immunity 5(1): 121-133 (2020) | Resumen: | In most HIV-infected persons, the natural history of untreated infection is one of sustained viremia, progressive CD4 T cell depletion with resultant morbidity and mortality. The advent of effective combination antiretroviral therapy (ART) that controls HIV replication has altered this landscape dramatically. Yet a rare population of HIV-infected persons—elite controllers (EC)—can control HIV replication such that plasma levels of virus are “undetectable” without ART. The EC phenotype is heterogeneous, with some subjects durably controlling the virus—persistent elite controllers—and some eventually losing viral control—transient elite controllers. Overall, EC tend to have robust HIV-specific T cell responses and in some cases, mainly in transient elite controllers, elevated activation and inflammation indices that diminish with ART suggesting that endogenous defenses against this persistent pathogen come at the cost of heightened activation/inflammation. A limited data set suggests that cardiovascular disease risk as well as the occur-rence of other morbid events may be greater in the overall EC population than in treated HIV infection. ART in EC decreases activation indices but does not appear to increase circulating CD4 T cell numbers nor do we know if it alters clinical outcomes. Thus, it is difficult to recommend or discourage a decision to start ART in the EC population but the authors lean toward treatment particularly in those EC whose activation indices are high and those who are progressively losing circulating CD4 T cell numbers. Biomarkers that can reliably predict loss of virologic control and immune failure are needed. | Versión del editor: | http://doi.org/10.20411/pai.v5i1.364 | URI: | http://hdl.handle.net/10261/236380 | DOI: | 10.20411/pai.v5i1.364 | Identificadores: | doi: 10.20411/pai.v5i1.364 issn: 2469-2964 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
HIV_Elite_Controllers.pdf | 202,23 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
8
checked on 17-abr-2024
SCOPUSTM
Citations
11
checked on 07-may-2024
Page view(s)
123
checked on 07-may-2024
Download(s)
75
checked on 07-may-2024